REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy combo shows promise for Tough-to-Treat blood cancers
Disease control CompletedThis phase 2 trial tested the immunotherapy drug pembrolizumab (Keytruda) alone or combined with idelalisib or ibrutinib in 65 patients with chronic lymphocytic leukemia (CLL) or low-grade B-cell non-Hodgkin lymphoma (NHL) that had returned or stopped responding to treatment. The…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Experimental combo therapy shows promise for Tough-to-Treat lymphomas
Disease control CompletedThis phase 1/2 trial tested a new treatment for people with CD30-positive Hodgkin or non-Hodgkin lymphomas that returned or didn't respond to prior therapy. The treatment combines AFM13, an antibody that targets cancer cells, with natural killer (NK) cells from donated umbilical …
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC